Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
US |
|
Austco Healthcare Ltd
ASX:AHC
|
AU |
|
Itera ASA
OSE:ITERA
|
NO |
|
Finet Group Ltd
HKEX:8317
|
HK |
|
Bank of the Philippine Islands
OTC:BPHLY
|
PH |
|
Control Print Ltd
NSE:CONTROLPR
|
IN |
|
P
|
Pilatus Marine PCL
SET:PLT
|
TH |
|
E
|
EnterSoft SA
ATHEX:ENTER
|
GR |
Wall Street
Price Targets
VRTX Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
VRTX
is 557.95 USD
with a low forecast of 333.3 USD and a high forecast of 673.05 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VRTX's stock price target?
Price Target
557.95
USD
According to Wall Street analysts, the average 1-year price target for
VRTX
is 557.95 USD
with a low forecast of 333.3 USD and a high forecast of 673.05 USD.
What is Vertex Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
11%
For the last 14 years the
compound annual growth rate for
Vertex Pharmaceuticals Inc's revenue is
17%.
The projected
CAGR
for the next 3 years is
11%.
What is Vertex Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
17%
For the last 14 years the
compound annual growth rate for
Vertex Pharmaceuticals Inc's operating income is
24%.
The projected
CAGR
for the next 3 years is
17%.
What is Vertex Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
17%
For the last 14 years the
compound annual growth rate for
Vertex Pharmaceuticals Inc's net income is
42%.
The projected
CAGR
for the next 3 years is
17%.
